Alzheimer’s Drug Deemed Too Expensive for NHS
Eisai and Biogen’s Alzheimer’s drug Leqembi, also known as lecanemab, has been approved by the UK’s Medicines and Healthcare products Regulatory Agency as the first treatment to slow the progression of the disease. However, patients in Britain’s state-run NHS are unlikely to access it after the National Institute for Health and Care Excellence (NICE) deemed it too costly for widespread use.
POPULAR POSTS
Bluetongue outbreak in a Portuguese sheep farm has broken out
September 19, 2024
Austria says disaster fund to rise to 1 billion euros
September 19, 2024
Portugal gets help from Spain and Morocco in response to fires
September 19, 2024
Drought reduces Amazon rivers to historic lows
September 19, 2024
LIVE STREAM